Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Rodman & Renshaw reiterated its Buy rating on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), saying the company’s “best-in-class” safety profile should boost the commercial launch of Trulance for the treatment of chronic idiopathic constipation (CIC).
Trulance
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
“Discontinuation rates were low among patients given both drug and placebo (4 percent vs. 2 percent, respectively) and the most common discontinuation-causing event was diarrhea (2 percent for Trulance vs. 0.5 percent in placebo),” analyst Raghuram Selvaraju wrote in a note.
Meanwhile, Synergy is slated to kick off the Trulance launch campaign within the next couple of weeks, and will launch with a wholesale acquisition cost (WAC) of $353.48, effectively at parity with Linzess.
Selvaraju expects 2017 revenue of $53.6 million and $362 million in Trulance sales in 2018. The analyst also projects Synergy could turn sustainably profitable in early 2018.
Related Link: Takeda's Speculative Interest In Synergy Soothes Stomach Pains; Canaccord Says Buy
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The analyst also pointed out that investors should note that Trulance could be approved for treatment of IBS-C by the end of 2017 or early in 2018, assuming sNDA submission later this month and a statutory 10-month review period.
M&A Activity Backdrop
On the M&A front, Selvaraju the acquisition prospects for Synergy remain favorable and named Takeda Pharmaceutical Co Ltd (ADR) (OTC:TKPYY), AstraZeneca plc (ADR) (NYSE:AZN), Novartis AG (ADR) (NYSE:NVS) and Shire PLC (ADR) (NASDAQ:SHPG) as potential suitors.
“From our perspective, Synergy fits the bill of a favorable target in having: (1) positive safety and efficacy data from large, well-controlled clinical trials; (2) an approved drug with a validated mechanism of action; and (3) a significant customer base,” Selvaraju highlighted.
The analyst noted that the recent Johnson & Johnson (JNJ)’s acquisition of the Swiss biotech firm Actelion for $30 billion suggests that Synergy could be acquired at a favorable price.
Selvaraju added that Synergy could fetch a favorable price in the event of a takeover, “given the paucity of acquisition targets for large-cap pharmaceutical firms that possess the characteristics Synergy currently displays.”
At last check, shares of Synergy had fallen 3.06 percent to $5.51. Selvaraju has a price target of $18.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.